RxDoctor Payments Data

Ngoc An Phan, MD

Internal Medicine · Philadelphia, PANPI 1346246998

Payments from drug & device makers

$18,992in general payments, 2019–2025

Across 76 payments — averaging $249.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$15K
  • GSK$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$541
  • AstraZeneca$322
  • Johnson & Johnson$205
  • plus $485 from 9 others

What the payments were for

  • Speaking & faculty fees$13,30070%
  • Travel & lodging$9565%
  • Food & beverage$4,57824%
  • Education$1581%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,992 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$55,928
Medicare patients
139
Services billed
687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin304$374,517
ProliaDenosumab197$340,098
Rabeprazole Sodium464$336,846
FarxigaDapagliflozin Propanediol219$238,130
Trelegy ElliptaFluticasone/Umeclidin/Vilanter163$173,592
VascepaIcosapent Ethyl306$170,095
TrulicityDulaglutide92$128,992
KerendiaFinerenone95$96,649
EliquisApixaban73$83,583
Entecavir80$81,239
Dexlansoprazole DrDexlansoprazole149$79,982
LinzessLinaclotide96$78,823
OzempicSemaglutide50$75,789
RybelsusSemaglutide39$70,058
Fluticasone-SalmeterolFluticasone Propion/Salmeterol183$69,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$541$470,928392 claims
AstraZenecaFarxiga, Breztri Aerosphere$322$252,670236 claims
GSKTrelegy Ellipta, Breo Ellipta$1,199$196,215197 claims
Novo NordiskOzempic, Rybelsus$1,017$145,84789 claims
Lilly USA, LLCTrulicity$24$128,99292 claims
BayerKerendia$20$96,64995 claims
Astellas Pharma US IncMyrbetriq$95$58,56585 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →